Please see the following D.D. -Murocman
(The following from Johan/Yahoo board)
"A complete 180 pivot to R&D which turned very successful due to universities across Canada accruing interest in the Graphene derived from the Albany graphite. The resulting partnerships has allowed Zentek the opportunity to commercialize many IP developed in collaboration with their own researchers and experts across the country.
Now finalizing commercialization of the Anti-microbial compound which initialized a growing cult interest in the company. Those willing to put in the research do not have a hard time finding reasons to invest in what is turning into a burgeoning IP-spinoff company with primary focus on Healthcare.
Current commercial capacity suggests a procurement of around what is equivalent to material used to coat 9.6 billion masks, with ability to spread that production capacity into applications as they are approved, among which include:
Masks 1% of global >$200 mil/year, MASKS ALONE!
Gloves 1% of global >$50mil/year,
HVAC filters 1% of global >$150mil/year,
Medical Gowns, caps, booties,
Bedsheets,
High-touch surfaces,
Cardboard, paper, & other packaging material,
Bandages..
Much more
Compound also undergoing human trials next year for pharmaceuticals. Expected testing multiple skin conditions and gut infections. Early safety tests suggests this will be very safe with very high potency.
Further, the company expects to release a highly competitive rapid aptamer test for localized usage and results under 10 minutes. To be developed for everything from STD's to cancer. New aptamers are
expected to require an additional one to two months to be integrated within the pathogen detection
system
Will seek to develop:
(i) commercially synthesized aptamers for the detection of COVID-19;
(ii) aptamer deposition on screen printed electrodes;
(iii) an automated detector device that adds the fluidic buffers to the sensor and integrates a potentiostat which measures impedance indicating the presence of absence of the targeted pathogen; and
(iv) software that connects the detector to a device and management system.
A prototype of the system is expected to be completed in 2022, at which point a final commercialization strategy will be determined based on the market data. The Corporation then intends to request approval for the rapid test under the interim order provision at Health Canada.
As an IP development company, they are involved in many special projects:
• Ice-phobic coating, planes, pavement, power lines
• Anti-corrosive coating, heavy maritime potential
• Fuel additives, aerospace fuels, diesels and gasoline
• Concretes, small 0.02% graphene improves tensile and compressive strengths by >40-80%
• Batteries (mentioned recently by CEO but not much has been disclosed)
• 3D conductive filaments for a variety of applications,
• Graphene quantum dot synthesis and applications,
• Graphene synthesis, has secured patent rights for in-house production through Guelph University
• Upscaling recycled plastics,
• Magnetic filament fabrication,
According to information circular, any of these could justify another pilot plant scale application 2022.
As a results of being a graphite play, Zentek Ltd. retains ownership of the Albany deposit, of which is not priority but could be outsourced or sold to further pursue the intense future proofing that the IP could provide."
IMHO & Speculation this will be a $10 NASDAQ stock in 2022. Do your own D.D. & form your own conclusions
Chico
(The following from Johan/Yahoo board)
"A complete 180 pivot to R&D which turned very successful due to universities across Canada accruing interest in the Graphene derived from the Albany graphite. The resulting partnerships has allowed Zentek the opportunity to commercialize many IP developed in collaboration with their own researchers and experts across the country.
Now finalizing commercialization of the Anti-microbial compound which initialized a growing cult interest in the company. Those willing to put in the research do not have a hard time finding reasons to invest in what is turning into a burgeoning IP-spinoff company with primary focus on Healthcare.
Current commercial capacity suggests a procurement of around what is equivalent to material used to coat 9.6 billion masks, with ability to spread that production capacity into applications as they are approved, among which include:
Masks 1% of global >$200 mil/year, MASKS ALONE!
Gloves 1% of global >$50mil/year,
HVAC filters 1% of global >$150mil/year,
Medical Gowns, caps, booties,
Bedsheets,
High-touch surfaces,
Cardboard, paper, & other packaging material,
Bandages..
Much more
Compound also undergoing human trials next year for pharmaceuticals. Expected testing multiple skin conditions and gut infections. Early safety tests suggests this will be very safe with very high potency.
Further, the company expects to release a highly competitive rapid aptamer test for localized usage and results under 10 minutes. To be developed for everything from STD's to cancer. New aptamers are
expected to require an additional one to two months to be integrated within the pathogen detection
system
Will seek to develop:
(i) commercially synthesized aptamers for the detection of COVID-19;
(ii) aptamer deposition on screen printed electrodes;
(iii) an automated detector device that adds the fluidic buffers to the sensor and integrates a potentiostat which measures impedance indicating the presence of absence of the targeted pathogen; and
(iv) software that connects the detector to a device and management system.
A prototype of the system is expected to be completed in 2022, at which point a final commercialization strategy will be determined based on the market data. The Corporation then intends to request approval for the rapid test under the interim order provision at Health Canada.
As an IP development company, they are involved in many special projects:
• Ice-phobic coating, planes, pavement, power lines
• Anti-corrosive coating, heavy maritime potential
• Fuel additives, aerospace fuels, diesels and gasoline
• Concretes, small 0.02% graphene improves tensile and compressive strengths by >40-80%
• Batteries (mentioned recently by CEO but not much has been disclosed)
• 3D conductive filaments for a variety of applications,
• Graphene quantum dot synthesis and applications,
• Graphene synthesis, has secured patent rights for in-house production through Guelph University
• Upscaling recycled plastics,
• Magnetic filament fabrication,
According to information circular, any of these could justify another pilot plant scale application 2022.
As a results of being a graphite play, Zentek Ltd. retains ownership of the Albany deposit, of which is not priority but could be outsourced or sold to further pursue the intense future proofing that the IP could provide."
IMHO & Speculation this will be a $10 NASDAQ stock in 2022. Do your own D.D. & form your own conclusions
Chico
Recent ZTEK News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2026 01:50:43 PM
- Zentek's ZenGUARD(TM) Enhanced Air Filters Now Available for Direct Procurement by All Federal Departments and Agencies • Newsfile • 05/13/2026 11:35:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/06/2026 05:21:02 PM
- Zentek Accepting Canadian Commercial Orders for ZenGUARD(TM) Enhanced Air Filters Following Health Canada Regulatory Classification • Newsfile • 05/06/2026 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/28/2026 02:01:22 PM
- Albany Graphite Launches Year Two Environmental and Social Baseline Program with ERM and Constance Lake First Nation • Newsfile • 04/28/2026 11:33:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/22/2026 02:21:13 PM
- Albany Graphite Executes Agreement with AETC for Certified Samples and Process Engineering, Completing the Set of Three Independent Workstreams Feeding the PEA • Newsfile • 04/21/2026 11:57:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/16/2026 08:20:27 PM
- Albany Graphite Corp. Engages AppEco for Independent Market Research and Economic Analysis • Newsfile • 04/16/2026 02:55:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/15/2026 06:01:49 PM
- Triera Biosciences Completes Innovative Solutions Canada Contract, Advances Platform Toward New Candidate Development • Newsfile • 04/14/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/13/2026 02:06:25 PM
- Albany Graphite Corp. Engages Micon International to Complete New PEA for Albany Graphite Project • Newsfile • 04/09/2026 01:20:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 02:08:37 PM
- Zentek Engages ICP Securities Inc. for Automated Market Making Services • Newsfile • 04/01/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 02:37:13 PM
- Triera Biosciences - a Zentek Company - Launches Contract Research Organization Services for Custom Aptamer Discovery, Biosensor Enablement, and Machine-Learning Classification • ACCESS Newswire • 03/25/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/13/2026 02:33:34 PM
- Zentek Ltd. Receives Favorable Judgment in Long-Standing Litigation • ACCESS Newswire • 03/13/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/09/2026 08:55:20 PM
- Zentek Provides PDAC 2026 Update - Government and First Nations Engagement • ACCESS Newswire • 03/09/2026 08:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 03:50:24 PM
- Zentek Announces Pilot Evaluation Program with Quality Filters Inc. • ACCESS Newswire • 03/04/2026 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2026 10:19:17 PM
